2014
Oncologic Issues and Kidney Transplantation: A Review of Frequency, Mortality, and Screening
Asch WS, Bia MJ. Oncologic Issues and Kidney Transplantation: A Review of Frequency, Mortality, and Screening. Advances In Kidney Disease And Health 2014, 21: 106-113. PMID: 24359993, DOI: 10.1053/j.ackd.2013.07.003.BooksMeSH KeywordsAnus NeoplasmsBreast NeoplasmsCarcinoma, Renal CellColorectal NeoplasmsEarly Detection of CancerFemaleHumansImmunocompromised HostImmunosuppressive AgentsKidney Failure, ChronicKidney NeoplasmsKidney TransplantationLymphoproliferative DisordersNeoplasmsSkin NeoplasmsUterine Cervical NeoplasmsConceptsStandard incidence ratioKidney transplantationKidney transplant recipientsDevelopment of malignancyReview of frequencyTransplant recipientsIncidence ratiosCommon malignancyTreatment recommendationsTumor surveillanceOncologic issuesGeneral populationTumor growthMalignancyOncogenic virusesCurrent preventionTransplantationRiskEarly ageImmunosuppressantsReviewCancerMortalityRecipientsPrevention
2012
Patient Education to Reduce Disparities in Renal Transplantation
Asch WS, Bia MJ. Patient Education to Reduce Disparities in Renal Transplantation. Clinical Journal Of The American Society Of Nephrology 2012, 7: 527-529. PMID: 22403275, DOI: 10.2215/cjn.01770212.Commentaries, Editorials and Letters
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure